What is Roivant?
Founded in 2014 and headquartered in London, Roivant Sciences operates at the intersection of biotechnology and advanced data analytics. The company distinguishes itself through a decentralized model, creating subsidiary entities—or 'Vants'—that focus on specific therapeutic areas or healthcare technologies. This structure allows for agile decision-making and specialized focus, enabling the firm to efficiently navigate the complex drug development lifecycle. By integrating proprietary technology platforms with deep scientific expertise, Roivant aims to reduce the time and cost associated with bringing innovative treatments to market, thereby delivering significant value to patients and stakeholders alike.
How much funding has Roivant raised?
Roivant has raised a total of $1.4B across 3 funding rounds:
Private Equity
$100M
Private Equity
$1.1B
Private Equity
$200M
Private Equity (2014): $100M with participation from QVT Financial and Dexcel Pharma
Private Equity (2017): $1.1B led by Dexcel Pharma and Softbank
Private Equity (2018): $200M supported by RTW Investments and NovaQuest Capital Management
Key Investors in Roivant
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
Softbank
SoftBank Group Corp. is a global technology holding company driving innovation across telecommunications, internet services, artificial intelligence, and clean energy technologies.
Dexcel Pharma
Dexcel Pharma is Israel’s largest privately owned pharmaceutical company, developing and manufacturing value-added branded prescription drugs and generics.
What's next for Roivant?
With the support of its recent capital raise, Roivant is well-positioned to scale its pipeline and further integrate its digital health initiatives. The strategic focus will likely remain on the acquisition and development of high-potential drug candidates, alongside the expansion of its technological infrastructure. As the company matures, the emphasis will shift toward commercialization and the long-term sustainability of its diverse portfolio. Investors will be closely monitoring the firm's ability to translate its robust research and development efforts into tangible clinical outcomes, ensuring that its innovative healthcare solutions reach global markets effectively.
See full Roivant company page
